(Gastric Cancer) Nivolumab (Opdivo) Plus Ramucirumab (Cyramza) as Second-Line Therapy: NivoRam Phase 1/2 Study
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- March 13, 2019
- 1 min read
At the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2019), held in San Francisco from January 17–19, 2019, results from a Phase 1/2 clinical trial evaluating nivolumab (anti-PD-1 antibody) plus ramucirumab (anti-VEGF antibody) combination therapy as second-line treatment for advanced gastric cancer were presented.
The 6-month progression-free rate for this combination as second-line therapy in advanced gastric cancer patients was 37.4%.
Dr. Hiroki Hara analyzed the results and concluded that patients showed good tolerability to adverse events and favorable anti-tumor activity with this combination regimen.
Source: Phase I/II study of ramucirumab plus nivolumab in patients in second line treatment for advanced gastric adenocarcinoma (NivoRam study). ASCO-GI 2019, Abstract 129.
Gastric Cancer | Nivolumab | Ramucirumab | Second-Line Therapy
-
Clinical Trial Medications
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1